Literature DB >> 26002846

Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.

Patrick R Harrington1, Damon J Deming1, Takashi E Komatsu1, Lisa K Naeger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26002846     DOI： 10.1093/cid/civ402

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Authors:  Harel Dahari; Laetitia Canini; Frederik Graw; Susan L Uprichard; Evaldo S A Araújo; Guillaume Penaranda; Emilie Coquet; Laurent Chiche; Aurelie Riso; Christophe Renou; Marc Bourliere; Scott J Cotler; Philippe Halfon
Journal:  J Hepatol       Date:  2016-02-22       Impact factor: 25.083

2.  Reply to Harrington et al.

Authors:  Sreetha Sidharthan; Anita Kohli; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2015-05-22       Impact factor: 9.079

3.  Resurrection of response-guided therapy for sofosbuvir combination therapies.

Authors:  Harel Dahari; Phillippe Halfon; Scott J Cotler
Journal:  J Hepatol       Date:  2016-05-27       Impact factor: 25.083

4.  Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.

Authors:  Yaakov Hasin; Shimon Shteingart; Harel Dahari; Inna Gafanovich; Sharon Floru; Marius Braun; Amir Shlomai; Anthony Verstandig; Ilana Dery; Susan L Uprichard; Scott J Cotler; Yoav Lurie
Journal:  World J Hepatol       Date:  2016-07-18

Review 5.  Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.

Authors:  Rubesh Raja; Subhasish Baral; Narendra M Dixit
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

6.  Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

Authors:  Miguel Malespin; Tamara Benyashvili; Susan L Uprichard; Alan S Perelson; Harel Dahari; Scott J Cotler
Journal:  Therap Adv Gastroenterol       Date:  2016-10-17       Impact factor: 4.409

7.  SASLT guidelines: Update in treatment of Hepatitis C virus infection.

Authors:  Abdullah S Alghamdi; Mohammed Alghamdi; Faisal M Sanai; Hamdan Alghamdi; Faisal Aba-Alkhail; Khalid Alswat; Mohammed Babatin; Adel Alqutub; Ibrahim Altraif; Faleh Alfaleh
Journal:  Saudi J Gastroenterol       Date:  2016-08       Impact factor: 2.485

8.  Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents.

Authors:  Subhasish Baral; Rahul Roy; Narendra M Dixit
Journal:  Immunol Cell Biol       Date:  2018-06-05       Impact factor: 5.126
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.